🚀 VC round data is live in beta, check it out!
Galapagos Valuation Multiples
Discover revenue and EBITDA valuation multiples for Galapagos and similar public comparables like Celltrion Pharm, Bausch Health, Bavarian Nordic, Jafron Biomedical and more.
Galapagos Overview
About Galapagos
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
Founded
1999
HQ
Employees
704
Website
Sectors
Financials (LTM)
Market Cap
$2B
Galapagos Financials
Galapagos reported last 12-month revenue of $993M and EBITDA of $237M.
In the same LTM period, Galapagos generated $964M in gross profit, $237M in EBITDA, and $245M in net income.
Revenue (LTM)
Galapagos P&L
In the most recent fiscal year, Galapagos reported revenue of $1B and EBITDA of $411M.
Galapagos expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $993M | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $964M | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 97% | XXX | 95% | XXX | XXX | XXX |
| EBITDA | $237M | XXX | $411M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 31% | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 44% | XXX | XXX | XXX |
| Net Profit | $245M | XXX | $378M | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 29% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Galapagos Stock Performance
Galapagos has current market cap of $2B.
Market Cap Evolution
Galapagos' stock price is $34.00.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $2B | 0.0% | XXX | XXX | XXX | $5.73 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGalapagos Valuation Multiples
Galapagos trades at (1.3x) EV/Revenue multiple, and (5.6x) EV/EBITDA.
EV / Revenue (LTM)
Galapagos Financial Valuation Multiples
As of April 2, 2026, Galapagos has market cap of $2B.
Equity research analysts estimate Galapagos' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Galapagos has a P/E ratio of 9.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | ($1B) | XXX | ($1B) | XXX | XXX | XXX |
| EV/Revenue | (1.3x) | XXX | (1.0x) | XXX | XXX | XXX |
| EV/EBITDA | (5.6x) | XXX | (3.2x) | XXX | XXX | XXX |
| EV/EBIT | (8.0x) | XXX | (2.3x) | XXX | XXX | XXX |
| EV/Gross Profit | (1.4x) | XXX | (1.1x) | XXX | XXX | XXX |
| P/E | 9.1x | XXX | 5.9x | XXX | XXX | XXX |
| EV/FCF | 6.6x | XXX | 8.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Galapagos Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Galapagos Margins & Growth Rates
Galapagos' revenue in the last 12 month declined by (96%).
Galapagos' revenue per employee in the last FY averaged $1.9M, while opex per employee averaged $0.9M for the same period.
Galapagos' rule of 40 is (589%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Galapagos' rule of X is (734%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Galapagos Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (96%) | XXX | (97%) | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Growth | (182%) | XXX | (146%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (589%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (734%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.9M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 47% | XXX | 41% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Galapagos Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Celltrion Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Bausch Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Bavarian Nordic | XXX | XXX | XXX | XXX | XXX | XXX |
| Jafron Biomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| Lotus Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Galapagos M&A Activity
Galapagos acquired XXX companies to date.
Last acquisition by Galapagos was on XXXXXXXX, XXXXX. Galapagos acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Galapagos
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGalapagos Investment Activity
Galapagos invested in XXX companies to date.
Galapagos made its latest investment on XXXXXXXX, XXXXX. Galapagos invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Galapagos
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Galapagos
| When was Galapagos founded? | Galapagos was founded in 1999. |
| Where is Galapagos headquartered? | Galapagos is headquartered in United States. |
| How many employees does Galapagos have? | As of today, Galapagos has over 704 employees. |
| Who is the CEO of Galapagos? | Galapagos' CEO is Paulus Stoffels. |
| Is Galapagos publicly listed? | Yes, Galapagos is a public company listed on Nasdaq. |
| What is the stock symbol of Galapagos? | Galapagos trades under GLPG ticker. |
| When did Galapagos go public? | Galapagos went public in 2008. |
| Who are competitors of Galapagos? | Galapagos main competitors are Celltrion Pharm, Bausch Health, Bavarian Nordic, Jafron Biomedical. |
| What is the current market cap of Galapagos? | Galapagos' current market cap is $2B. |
| What is the current revenue of Galapagos? | Galapagos' last 12 months revenue is $993M. |
| What is the current revenue growth of Galapagos? | Galapagos revenue growth (NTM/LTM) is (96%). |
| What is the current EV/Revenue multiple of Galapagos? | Current revenue multiple of Galapagos is (1.3x). |
| Is Galapagos profitable? | Yes, Galapagos is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Galapagos? | Galapagos' last 12 months EBITDA is $237M. |
| What is Galapagos' EBITDA margin? | Galapagos' last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Galapagos? | Current EBITDA multiple of Galapagos is (5.6x). |
| What is the current FCF of Galapagos? | Galapagos' last 12 months FCF is ($201M). |
| What is Galapagos' FCF margin? | Galapagos' last 12 months FCF margin is (20%). |
| What is the current EV/FCF multiple of Galapagos? | Current FCF multiple of Galapagos is 6.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.